Niagen Bioscience Inc

NASDAQ:NAGE

Biotechnology

Healthcare
$1.94 +3.31%

+$0.11 today

Market cap
$153.64M
Beta
2.06
P/E (TTM)
14.9
EPS (TTM)
$0.23
52W Low $3.35High $14.69

Volume 0.52M

Average 0.86M

NAGE Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Niagen Bioscience IncNASDAQ: NAGE

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $2.48M rose 17.8% year over year, ahead of the -21.6% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 1.8% of revenue in FY2025, up 0.7 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.8% holds above the trailing-twelve-month pace of -21.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.48M+227.5% QoQ
Last fiscal yearDec 2025
$2.27M+312.7% YoY
LTMMar 2026
$2.65M-21.6% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.8%——
1 year+312.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
2.27M USD
Year-over-year change
+312.7%
4-year CAGR
+23.4%

Accounts Payables vs competitors

How NAGE compares with its peers on the latest reported figures

  • NAGE's LTM Mar 2026 accounts payables of $2.65M is the 6th largest of the 10 companies compared; the peer median is $459K.
  • Its year-over-year change of -21.6% is the 7th highest of 9, against a peer median of +130.8%.
  • Accounts payables amounts to 2.0% of revenue for NAGE, versus a peer median of 2.0%.
NAGE Competitors Peer median
Accounts Payables for NAGE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$18.91M +528.3%—32.6%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$8.85M +148.8%—7.2%
KROSKeros Therapeutics, Inc.LTM Mar 2026$5.13M -393.5%+94.5%15.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$3.39M +1225.9%——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$3.23M +147.7%+135.7%—
NAGENiagen Bioscience IncLTM Mar 2026$2.65M -21.6%—2.0%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$2.48M -163.4%+27.1%1.1%
RGNXREGENXBIO Inc.LTM Mar 2026$1.72M +113.8%—2.0%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$532K +110.0%+0.6%0.2%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$459K ——0.4%
Peer median (excluding NAGE) $459K+130.8%+60.8%2.0%

Competitors are the stored peer set for NAGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.13M)(16.54M)(4.94M)8.55M17.38M
Depreciation & Amortization1.63M1.88M1.71M1.48M1.45M
Deferred Income Tax00000
Stock-Based Compensation6.2M5.74M4.75M3.66M6.07M
Change in Working Capital(4.73M)(6.01M)4.62M3.13M(8.3M)
Accounts Receivables(2.58M)(3.32M)2.26M(1.28M)(756K)
Inventory(1.92M)(1.08M)152K5.33M(11.64M)
Accounts Payables978K(744K)553K(1.07M)2.27M
Other Working Capital(1.21M)(875K)1.66M147K1.83M
Other Non-Cash Items(124K)(167K)977K(4.72M)(3.17M)
Operating Cash Flow(24.16M)(15.1M)7.12M12.11M13.44M
Capital Expenditures(409K)(334K)(148K)(163K)(292K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities005K20K0
Investing Cash Flow(409K)(334K)(143K)(143K)(292K)
Debt Repayment(31K)(16K)(15K)(11K)(12K)
Common Stock Issued26.74M7.75M05.43M7.25M
Common Stock Repurchased0000(251K)
Dividends Paid00000
Other Financing Activities9.39M(77K)(75K)(52K)0
Financing Cash Flow36.09M7.65M(90K)5.37M6.98M
Effect of Forex Changes00000
Net Change in Cash11.52M(7.78M)6.88M17.34M20.13M
Free Cash Flow(24.57M)(15.43M)6.97M11.95M13.15M

Niagen Bioscience Inc

NASDAQ:NAGE

Intrinsic Alpha fair value

Locked

Current Price

$1.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.